Eli Lilly and Company

Synnovation Therapeutics Launches with $102 Million to Advance Clinical-Stage Pipeline of Precision Therapies Targeting Highly Validated Disease Pathways

Retrieved on: 
Wednesday, January 24, 2024
Pharmaceutical, Health, Oncology, Other Health, Entrepreneurship, Vitiligo, Patient, Incyte, Therapy, Rheumatoid arthritis, JAK, Third Rock Ventures, Molecular biology, Pharmacology, Cancer, Medicine, Drug discovery, FGFR, Cholangiocarcinoma, Ruxolitinib, Non-small-cell lung cancer, COVID-19, Atopic dermatitis, PARP1, FDA, Polycythemia, Eli Lilly and Company, Medicinal chemistry, Drug, EVP, GPH, CNS, Pharmaceutical industry

Synnovation Therapeutics, a precision medicine company developing small molecule therapies optimized to achieve best-in-class pharmacology against highly validated disease targets, launched today with a $102 million Series A.

Key Points: 
  • Synnovation Therapeutics, a precision medicine company developing small molecule therapies optimized to achieve best-in-class pharmacology against highly validated disease targets, launched today with a $102 million Series A.
  • Synnovation was founded by a world-class medicinal chemistry team with a track record of developing best-in-class therapeutics.
  • Proceeds will fund the advancement of the company’s clinical and preclinical pipeline, including SNV1521 and SNV4818, as well as additional programs.
  • The company’s lead program, SNV1521, is a potentially best-in-class, potent, highly selective and CNS penetrant PARP1 inhibitor.

Napoli Shkolnik 2023 In Review: Law Firm Reaches Groundbreaking Victories for Victims of Water Contamination; Important Litigation Filed in Insulin Pricing Scheme, Air Pollution, and More

Retrieved on: 
Wednesday, January 24, 2024
Legal, Professional Services, Learning, PFAS, UnitedHealth Group, AFFF, Drinking water, Trauma center, Sanofi, City, Injury, Insurance, Curriculum, P.C, Massage, Risk, Corteva, Federation, Insulin, Pharmacy, Eli Lilly and Company, Cancer, Water, 3M, MDL, Class Action, Pregnancy, Atmosphere, Express Scripts, Pain, Ethylene oxide, Plaintiff, Pharmaceutical industry

National law firm Napoli Shkolnik has concluded another successful year of landmark settlements and significant legal action in the areas of environmental litigation, mass tort, and human rights.

Key Points: 
  • National law firm Napoli Shkolnik has concluded another successful year of landmark settlements and significant legal action in the areas of environmental litigation, mass tort, and human rights.
  • Among the firm’s accomplishments of 2023 were significant breakthroughs in the ongoing multidistrict litigation (MDL) against manufacturers of aqueous film-forming foam (AFFF).
  • The funds will go to cities, towns and other public water providers over a 13-year period to test for and treat PFAS contamination.
  • The program’s rigorous and enriching curriculum is designed to continue Napoli Shkolnik’s legacy of delivering justice for their clients.

GlobalData report highlights staggering economic costs for South Carolina of $7.4 billion due to obesity

Retrieved on: 
Wednesday, January 17, 2024
Labor, Fitness & Nutrition, Public Policy, Government, Healthcare Reform, Business, Professional Services, Health, State, Local, General Health, Welfare, Conditional sentence, Woman, Death, Medicaid, Weight loss, Culture, Medicare, Insurance, Federation, Eli Lilly and Company, Parity, Disease, DSM-IV codes, Workforce, Head, Overweight, GlobalData, Education, Pharmaceutical industry

GlobalData’s report, ‘ Obesity’s Impact on South Carolina's Economy and Labor Force ,’ analyzes the economic and workforce implications of obesity in the State of South Carolina, as well as the impact on state tax revenue collections and costs.

Key Points: 
  • GlobalData’s report, ‘ Obesity’s Impact on South Carolina's Economy and Labor Force ,’ analyzes the economic and workforce implications of obesity in the State of South Carolina, as well as the impact on state tax revenue collections and costs.
  • In South Carolina, approximately one-third of adults are classified as having obesity (35.0%), and another third have overweight (34.8%) in 2022.
  • Employers in South Carolina paid an extra $907 million in higher medical expenditures for health complications attributed to obesity and overweight.
  • The federal government also spent an estimated $1.7 billion more on Medicare and Medicaid for South Carolina residents.

Johna Norton to Retire as Lilly Executive Vice President of Global Quality

Retrieved on: 
Thursday, January 25, 2024
Patient, Research, Executive Committee, Woman, Eli Lilly and Company, Quality control, Retirement, LLY, Pharmaceutical industry

INDIANAPOLIS, Jan. 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Johna Norton, executive vice president of Global Quality, will be retiring after 34 years of service with the company, effective July 31, 2024.

Key Points: 
  • INDIANAPOLIS, Jan. 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Johna Norton, executive vice president of Global Quality, will be retiring after 34 years of service with the company, effective July 31, 2024.
  • "Johna's career has been built on her commitment to ensuring that our medicines are produced with the highest quality standards.
  • "During her tenure as leader of Global Quality, Johna has overseen significant expansion, modernization of systems and improvements in our processes and team.
  • Norton has been with Lilly since 1990, starting as an analytical chemist and moving on to hold various leadership positions in quality assurance and quality control.

Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting

Retrieved on: 
Tuesday, January 23, 2024
Child, Hearing loss, Lilly, Clinical trial, Gene, Medicine, Sant Joan, ABR, Eli Lilly and Company, Genetic testing, Division, HL, Hospital, ARO, FDA, Physician, Late, Hearing, Research, Diagnosis, LLY, SVP, Pharmaceutical industry

INDIANAPOLIS, Jan. 23, 2024 /PRNewswire/ -- Akouos, Inc., a wholly owned subsidiary of Eli Lilly and Company (NYSE: LLY), today announced positive initial clinical results from the Phase 1/2 AK-OTOF-101 study, which demonstrated pharmacologic hearing restoration within 30 days of AK-OTOF administration in the first participant, an individual with a decade-plus history of profound hearing loss. Results, including initial data from a second participant to receive AK-OTOF, will be presented during the Late Breaking Presidential Symposium at the 2024 Association for Research in Otolaryngology (ARO) MidWinter Meeting.

Key Points: 
  • Results, including initial data from a second participant to receive AK-OTOF, will be presented during the Late Breaking Presidential Symposium at the 2024 Association for Research in Otolaryngology (ARO) MidWinter Meeting.
  • Both the surgical administration procedure and the investigational therapy were well tolerated, and no serious adverse events were reported.
  • Millions of individuals worldwide have disabling hearing loss because one of their genes generates an incorrect or incomplete version of a protein the ear requires for hearing.
  • OTOF-mediated hearing loss is the first monogenic form of hearing loss to be investigated as part of a gene therapy clinical trial.

Lilly Confirms Date and Conference Call for Fourth-Quarter 2023 Financial Results and 2024 Financial Guidance

Retrieved on: 
Tuesday, January 23, 2024
Eli Lilly and Company, LLY, Lilly, Pharmaceutical industry

INDIANAPOLIS, Jan. 23, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2023 financial results and 2024 financial guidance on Feb. 6, 2024.

Key Points: 
  • INDIANAPOLIS, Jan. 23, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2023 financial results and 2024 financial guidance on Feb. 6, 2024.
  • Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance and guidance.
  • Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations .
  • A replay will also be available on the website following the conference call.

KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS

Retrieved on: 
Thursday, January 18, 2024
Corporation, Executive Committee, Temple University, Antares, Lilly, Eli Lilly and Company, KZIA, Eli Lilly, Acquisition, Carmine, Finance, Marketing, Growth, Management

Mr. Apple also served on the Board of Directors at Antares from 2016 until May 2022.

Key Points: 
  • Mr. Apple also served on the Board of Directors at Antares from 2016 until May 2022.
  • He previously served on the Boards of Directors of InKine Pharmaceutical, PaxMedica Inc., and Kerathin Inc.
  • In a further renewal of the Board, Non-Executive Director Mr. Bryce Carmine has been appointed Chairman.
  • Commenting on the Board appointments, Kazia's CEO Dr. John Friend said: "We are delighted that Bryce has accepted the role of Chairman and that Bob has agreed to join the Board.

Non-Alcoholic Steatohepatitis Treatment Drug Market In Japan is Expected to Showcase Impressive Growth by 2032 | DelveInsight

Retrieved on: 
Wednesday, January 17, 2024
Obesity, Merck & Co., MRI, LAS, Weight loss, Fatty liver disease, Type 2 diabetes, Magnetic resonance imaging, Insulin resistance, NASH, FFAR4, Liver, Liver disease, Diabetes, Alcoholic liver disease, Therapy, Hypertension, PPAR, Eli Lilly and Company, Gilead Sciences, Chronic pain, Disease, Inflammation, FASN, AstraZeneca, Novo Nordisk, FXR, Prevalence, CCR5, FGF, Physical examination, Weakness, Bronchial thermoplasty, Cilofexor, Metabolic syndrome, Mitsubishi Tanabe Pharma, Development, NAFLD, Risk, Fibrosis, Fatigue, Dyslipidemia, USD, Non-alcoholic fatty liver disease, Merck, Pharmaceutical industry

LAS VEGAS, Jan. 17, 2024 /PRNewswire/ -- DelveInsight's Non-Alcoholic Steatohepatitis Market Insights report includes a comprehensive understanding of current treatment practices, non-alcoholic steatohepatitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into Japan.

Key Points: 
  • LAS VEGAS, Jan. 17, 2024 /PRNewswire/ -- DelveInsight's Non-Alcoholic Steatohepatitis Market Insights report includes a comprehensive understanding of current treatment practices, non-alcoholic steatohepatitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into Japan.
  • According to DelveInsight's analysis, the market size for NASH reached USD 200 million in 2022 in Japan and is expected to grow with a significant CAGR by 2032.
  • DelveInsight's analysis reveals that the overall diagnosed prevalent population of NASH in Japan was reported as 2.5 million in 2022.
  • Among the forecasted emerging therapies, MGL-3196 (Resmetirom) is expected to capture the highest market in Japan by 2032.

Non-Alcoholic Steatohepatitis Treatment Drug Market In Japan is Expected to Showcase Impressive Growth by 2032 | DelveInsight

Retrieved on: 
Wednesday, January 17, 2024
Obesity, Merck & Co., MRI, LAS, Weight loss, Fatty liver disease, Type 2 diabetes, Magnetic resonance imaging, Insulin resistance, NASH, FFAR4, Liver, Liver disease, Diabetes, Alcoholic liver disease, Therapy, Hypertension, PPAR, Eli Lilly and Company, Gilead Sciences, Chronic pain, Disease, Inflammation, FASN, AstraZeneca, Novo Nordisk, FXR, Prevalence, CCR5, FGF, Physical examination, Weakness, Bronchial thermoplasty, Cilofexor, Metabolic syndrome, Mitsubishi Tanabe Pharma, Development, NAFLD, Risk, Fibrosis, Fatigue, Dyslipidemia, USD, Non-alcoholic fatty liver disease, Merck, Pharmaceutical industry

LAS VEGAS, Jan. 17, 2024 /PRNewswire/ -- DelveInsight's Non-Alcoholic Steatohepatitis Market Insights report includes a comprehensive understanding of current treatment practices, non-alcoholic steatohepatitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into Japan.

Key Points: 
  • LAS VEGAS, Jan. 17, 2024 /PRNewswire/ -- DelveInsight's Non-Alcoholic Steatohepatitis Market Insights report includes a comprehensive understanding of current treatment practices, non-alcoholic steatohepatitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into Japan.
  • According to DelveInsight's analysis, the market size for NASH reached USD 200 million in 2022 in Japan and is expected to grow with a significant CAGR by 2032.
  • DelveInsight's analysis reveals that the overall diagnosed prevalent population of NASH in Japan was reported as 2.5 million in 2022.
  • Among the forecasted emerging therapies, MGL-3196 (Resmetirom) is expected to capture the highest market in Japan by 2032.

Comanche Biopharma Closes Oversubscribed $75 Million Series B Financing to Advance Mission to Develop and Make Globally Available the First Treatment Targeting a Root Cause of Preeclampsia

Retrieved on: 
Wednesday, January 17, 2024
Death, Commissioner, Woman, Placenta, Patient, Intensive care medicine, Pre-eclampsia, Incidence, GV, Health, LAV, Series, Seizure, Nobel, Survivor, Stroke, New Enterprise Associates, Atlas, Small RNA, Medicine, Infant, Atlas Venture, Place of birth, Risk, Food, Pregnancy, Disease, Safety, FDA, Therapy, Capital, GV (company), Venture round, Eli Lilly and Company, Population health, NEA, Diagnosis, Trial of the century, Physician, Growth, Dietary supplement

Preeclampsia is a prevalent and serious pregnancy complication that affects approximately 10 million women globally each year.

Key Points: 
  • Preeclampsia is a prevalent and serious pregnancy complication that affects approximately 10 million women globally each year.
  • It can lead to serious complications for both the mother and the baby, including multi-organ damage, seizures, and premature birth.
  • Currently, delivery of the baby, often very prematurely, is the only available option for stopping the progression of preeclampsia.
  • Scott Johnson, M.D., Chief Executive Officer at Comanche Biopharma, commented, “We are thrilled to have the support and validation of this top-tier investor syndicate.